Fulminant hepatitis-A in a child using sodium valproate therapy: Case report

Basit Öğe Kaydı
dc.authorscopusid6506958982
dc.authorscopusid55197766400
dc.authorscopusid35502849500
dc.authorscopusid6504799643
dc.authorscopusid6602546507
dc.contributor.authorÇeltik C.
dc.contributor.authorTuran Ç.
dc.contributor.authorAcipayam C.
dc.contributor.authorKüçüku?urluo?lu Y.
dc.contributor.authorKarasaliho?lu S.
dc.date.accessioned2024-06-12T10:28:38Z
dc.date.available2024-06-12T10:28:38Z
dc.date.issued2010
dc.description.abstractThe risk of fulminant liver failure due to hepatitis A infection increases in the patients with underlying chronic liver diseases and hepatotoxic drug-use. In this case report, we aimed to emphasize the development of fulminant liver failure due to hepatitis A infection and importance of hepatitis A vaccination in these cases. A five-year age boy who treated with sodium valproate for three years was admitted with the symptoms of fulminant liver failure and encephalopathy to our emergency clinic. Hepatitis A IgM-antibody was found positive and serum sodium valproate level was mildly elevated. In conclusion, fulminant progression risk due to hepatitis-A infection increase in the patients using hepatotoxic drug such as sodium valproate. Therefore, hepatitis-A vaccination for these cases is important for decreasing the risk of fulminant hepatitis. Copyright © 2010 by Türkiye Klinikleri.en_US
dc.identifier.endpage179en_US
dc.identifier.issn1300-0381
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-77953790531en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage176en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17344
dc.identifier.volume19en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofTurkiye Klinikleri Pediatrien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChild; Hepatic Encephalopathy; Hepatitis A; Hepatitis A Vaccines; Liver Failure, Acute; Valproic Aciden_US
dc.subjectAlanine Aminotransferase; Aspartate Aminotransferase; Carnitine; Flumazenil; Hepatitis A Antibody; Hepatitis A Vaccine; Immunoglobulin M Antibody; Lactulose; Levodopa; Penicillin G; Ranitidine; Valproic Acid; Vitamin K Group; Antibody Titer; Article; Case Report; Child; Drug Blood Level; Electroencephalogram; Emergency Ward; Febrile Convulsion; Hepatic Encephalopathy; Hepatitis A; Human; Liver Failure; Male; Preschool Childen_US
dc.titleFulminant hepatitis-A in a child using sodium valproate therapy: Case reporten_US
dc.title.alternativeSodyum valproat tedavisi alan bir çocukta fulminan hepatit-Aen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu